Form 8-K - Current report:
SEC Accession No. 0001104659-25-015015
Filing Date
2025-02-19
Accepted
2025-02-19 09:22:24
Documents
15
Period of Report
2025-02-18
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm255723d4_8k.htm   iXBRL 8-K 50481
2 EXHIBIT 1.1 tm255723d4_ex1-1.htm EX-1.1 181144
  Complete submission text file 0001104659-25-015015.txt   524841

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA abbv-20250218.xsd EX-101.SCH 4501
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE abbv-20250218_def.xml EX-101.DEF 30265
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE abbv-20250218_lab.xml EX-101.LAB 40526
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abbv-20250218_pre.xml EX-101.PRE 28469
18 EXTRACTED XBRL INSTANCE DOCUMENT tm255723d4_8k_htm.xml XML 11751
Mailing Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064
Business Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 (847) 932-7900
AbbVie Inc. (Filer) CIK: 0001551152 (see all company filings)

EIN.: 320375147 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35565 | Film No.: 25637670
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)